ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO475

SGLT2 Inhibitor Therapy Ameliorates Anemia in Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical

Authors

  • Li, Chuanlei, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong
  • Szeto, Cheuk-Chun, The Chinese University of Hong Kong Faculty of Medicine, Hong Kong, Hong Kong
Background

Sodium glucose cotransporter 2 inhibitor (SGLT2i) is a standard treatment for kidney and cardiovascular protection in diabetic kidney disease (DKD). Recent evidence suggests that SGLT2i may enahnce erythropoietin production. We perform a retrospective cohort study to determine the effect of SGLT2i on the hemoglobin level in patients with DKD.

Methods

We reviewed 670 DKD patients started on SGLT2i. Their hemoglobin level and estimated glomerular filtration rate (eGFR) 6 months before the use of SGLT2i, immediately before, and 6 months after the use of SGLT2i were reviewed.

Results

The hemoglobin level had a small but significant increase 6 months after SGLT2 inhibitor treatment from 12.89 ± 1.75 to 13.08 ± 1.94 g/dL (p < 0.0001). The absolute increase in hemoglobin level was 0.19 ± 1.06 g/dL; 274 patients (40.9%) had hemoglobin increase ≥ 0.5 g/dL, and 117 (17.5%) had an increase ≥1.0 g/dL. In contrast, the average hemoglobin level was 13.01 ± 1.75 g/dL 6 months before SGLT2i, which showed a significant decline to the pre-treatment level (p=0.001). The increase in hemoglobin after SGLT2i was most marked in CKD stage 3b (12.26 ± 1.81 to 12.68 ± 1.98 g/dL, p < 0.0001). There was no significant correlation between the change in hemoglobin level and the severity of albuminuria or HbA1c level.

Conclusion

SGLT2i has a small but significant beneficial effect on DKD-related anemia. The clinical impact of this effect deserves further studies.

Funding

  • Clinical Revenue Support